Game-changing class of immunotherapy drugs lengthens melanoma survival rates

From Nature, 22 April 2020:

When Jedd Wolchok began working in the area of melanoma 20 years ago, the average life expectancy for a patient with advanced disease was six or seven months.

Now his waiting room is full of people coming back for their third or fourth year of follow-up, sharing their stories of survival with the newly diagnosed, giving hope where just a decade ago there was little.

“That gives you a sense of the human impact of this,” says Wolchok, a medical oncologist and director of the Parker Institute for Cancer Immunotherapy at the Memorial Sloan Kettering Cancer Center in New York, ranked fifth in the Nature Index for cancer research output. Read more.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s